Introgen`s Intravenously Administered Gene Therapy Demonstrates Safety And Establishes Basis for Systemic Treatment for Metastatic Cancer
(PR Newswire)...This demonstrates a huge margin of safety to our treatment which is in Phase III testing, delivered intratumorally to tumors in the head and neck.......Introgen is also conducting a Phase II clinical trial for INGN 201 in lung cancer and Phase I trials for INGN 201 in additional cancer indications including prostate, ovarian, bladder, brain, and breast cancer....- May 14 4:00 PM ET
IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source: http://biz.yahoo.com/prnews/010514/dam010b.html
(Everything below this line is from VirtualTrials.com!)
Click HERE to return to brain tumor news headlines